| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$30,518 |
Update - Notification of buy-back - BXB
|
30 Apr 2025 8:32AM |
$20.130 |
$22.630 |
risen by
12.42%
|
|
| Lark Distilling Co. Ltd (LRK) ORDINARY FULLY PAID |
Consumer Staple |
$99 |
March 2025 Quarterly Update and Appendix 4C
|
30 Apr 2025 8:32AM |
$0.885 |
$0.925 |
risen by
4.52%
|
|
LRK - Price-sensitive ASX Announcement
Full Release
Key Points
- Sales growth achieved in both domestic and international markets, driven by direct-to-consumer and e-commerce channels.
- Progress on premium whisky strategy, with focus on product innovation and brand development.
- Improved inventory and cost management contributing to positive cash flow.
- Continued investment in marketing, new product launches, and strategic partnerships.
- Strong cash position maintained, with detailed cash flow reporting in Appendix 4C.
- Ongoing focus on operational efficiency and capital allocation to support growth objectives.
- Updates on new product releases and expansion into new markets.
- Commitment to maintaining a leading position in the Australian whisky market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Top End Energy Limited (TEE) ORDINARY FULLY PAID |
Energy |
$10 |
Quarterly Activities Report
|
30 Apr 2025 8:31AM |
$0.076 |
$0.037 |
fallen by
51.32%
|
|
TEE - Price-sensitive ASX Announcement
Full Release
Key Points
- TEE continued exploration efforts in the Northern Territory and Queensland during the quarter.
- Regulatory submissions and community engagement were undertaken to progress project approvals.
- Technical work included seismic data reprocessing and environmental assessments.
- The company focused on moving its priority permits to drill-ready status.
- Strong relationships with stakeholders and local communities were maintained.
- TEE ensured it has sufficient capital to fund ongoing and planned activities.
- The company remains optimistic about the potential of its project portfolio.
- TEE is committed to advancing exploration and delivering shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Traka Resources Limited (TKL) ORDINARY FULLY PAID |
Materials |
- |
Quarterly Activity and Cashflow Report
|
30 Apr 2025 8:31AM |
$0.002 |
$0.003 |
risen by
25%
|
|
TKL - Price-sensitive ASX Announcement
Full Release
Key Points
- Exploration focused at Mt Cattlin North Project with drilling conducted during the quarter.
- Assay results from Mt Cattlin North confirm presence of pegmatite and lithium mineralization.
- Musgraves and Gorge Creek Projects remain prospective but had limited activity this quarter.
- Company completed a capital raising of $0.4 million to fund exploration activities.
- Cash outflows for the quarter totaled approximately $0.55 million, mainly for exploration.
- No mining production or development activities reported during the period.
- Traka Resources remains debt-free and well positioned for the next stage of exploration.
- Planned future work includes further drilling, geochemical surveys, and evaluating project opportunities.
- Board and management remain focused on delivering value to shareholders through exploration success.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$111 |
Quarterly Activities & Cashflow Report
|
30 Apr 2025 8:31AM |
$0.150 |
$0.375 |
risen by
150%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- ISLA-101 Phase 2a PEACH clinical trial for dengue fever progressed with the opening of the first site in Puerto Rico.
- First-in-patient clinical trial anticipated to begin enrolling in the second half of 2024.
- Ongoing engagement with global health and infectious disease organizations for partnerships and funding.
- Robust financial position with $5.23 million in cash at the end of the quarter.
- Active pursuit of business development and partnership opportunities.
- Focus on infectious diseases and developing a pipeline beyond dengue.
- Commitment to delivering clinical and corporate milestones to maximize shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Top End Energy Limited (TEE) ORDINARY FULLY PAID |
Energy |
$10 |
Appendix 5B
|
30 Apr 2025 8:31AM |
$0.076 |
$0.037 |
fallen by
51.32%
|
|
TEE - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarter covers activities from 1 January to 31 March 2023.
- Top End Energy Limited (TEE) focused on exploration and evaluation of assets in the Northern Territory and Queensland.
- Progress updates on EP 258 and EP 259, including engagement with regulatory authorities and stakeholders.
- Exploration activities included data review, planning for upcoming ground operations, and ongoing desktop studies.
- Regulatory progress for Queensland tenure, including application processes and environmental considerations.
- Ongoing community and stakeholder engagement to support exploration programs.
- Summary of cash flows for the quarter, highlighting operating, investing, and financing activities in accordance with Appendix 5B requirements.
- Cash at end of quarter and estimated cash outflows for the next quarter are reported.
- No significant changes in related party payments during the quarter.
- TEE continues to evaluate new opportunities to enhance its exploration portfolio while maintaining fiscal discipline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Peoplein Limited (PPE) ORDINARY FULLY PAID |
Industrials |
$65 |
Q3 FY25 financial results impacted by weather events
|
30 Apr 2025 8:31AM |
$0.790 |
$0.590 |
fallen by
25.32%
|
|
PPE - Price-sensitive ASX Announcement
Full Release
Key Points
- Peoplein Limited released Q3 FY25 financial results.
- The PPE workforce segment was notably affected by severe weather events and safety restrictions.
- Reduced demand and deployment of PPE staff negatively impacted revenue.
- Management identified the weather disruptions as extraordinary circumstances for the quarter.
- The company is implementing cost-control measures and exploring service diversification.
- Future mitigation plans are in place to address similar external risks.
- Operational resilience and risk monitoring are current strategic priorities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nido Education Limited (NDO) ORDINARY FULLY PAID |
Consumer Discretionary |
$79 |
Update - Notification of buy-back - NDO
|
30 Apr 2025 8:31AM |
$0.800 |
$0.350 |
fallen by
56.25%
|
|
| G8 Education Limited (GEM) ORDINARY FULLY PAID |
Consumer Discretionary |
$131 |
Update - Notification of buy-back - GEM
|
30 Apr 2025 8:30AM |
$1.270 |
$0.170 |
fallen by
86.61%
|
|
| Airtasker Limited (ART) ORDINARY FULLY PAID |
Communication Services |
$122 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2025 8:30AM |
$0.305 |
$0.250 |
fallen by
18.03%
|
|
ART - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report provides an update on activities and cash flows for Q3 FY2024.
- Airtasker reported strong revenue growth compared to the previous corresponding period.
- Marketplace Gross Marketplace Volume (GMV) increased, supported by product and market enhancements.
- New features and product improvements were implemented to improve the customer experience.
- Cash receipts from customers were robust, reflecting healthy platform demand.
- Net operating cash outflows were primarily related to staff costs and investment in platform development.
- Airtasker continues to manage cash prudently, maintaining a solid cash balance at the end of the quarter.
- Strategic initiatives included ongoing expansion into international markets and strengthening the platform ecosystem.
- ASX listing rule 4.7C disclosures included explanations of expenditure and operational updates.
- No payments were made to related parties except for directors’ fees and remuneration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| VHM Limited (VHM) ORDINARY FULLY PAID |
Materials |
$75 |
MOU with Currumbin Minerals for the Goschen Project
|
30 Apr 2025 8:30AM |
$0.310 |
$0.240 |
fallen by
22.58%
|
|
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$30 |
Investor Presentation - Q3 FY25 Quarterly Update
|
30 Apr 2025 8:30AM |
$0.095 |
$0.062 |
fallen by
34.74%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- CurveBeam AI Limited operates in the orthopaedic imaging sector, specializing in weight-bearing CT technologies.
- The company serves markets in the U.S., Europe, and Asia-Pacific, with a focus on expanding its commercial footprint.
- Q3 FY25 saw revenue growth compared to previous quarters, driven by increased product adoption and market expansion.
- CurveBeam AI maintains a strong cash balance and continues to invest in R&D, sales, and marketing to support future growth.
- Recent milestones include key regulatory approvals, new product launches, and strategic partnerships with healthcare providers.
- The company highlights a significant market opportunity in musculoskeletal imaging as healthcare providers seek advanced diagnostic solutions.
- Management remains focused on executing the company’s growth strategy, leveraging proprietary technology and expanding its customer base.
- CurveBeam AI anticipates continued growth and innovation, supported by its experienced leadership team and industry partnerships.
- The Investor Presentation provides forward-looking statements regarding market expansion, product pipeline, and financial outlook.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GreenTech Metals Limited (GRE) ORDINARY FULLY PAID |
Materials |
$22 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:30AM |
$0.045 |
$0.080 |
risen by
77.78%
|
|
GRE - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden JORC Mineral Resource Estimate completed for Whundo Project.
- Drilling at Ruth Well confirmed nickel-copper sulphide mineralisation.
- Geophysical and geochemical surveys undertaken to identify new targets.
- Advancements in asset acquisition and strategic partnerships.
- Progress in environmental and heritage surveys for project areas.
- Successful capital raising to fund ongoing exploration activities.
- Completion of exploration expenditures and reporting of cash flow in Appendix 5B.
- Focus on Western Australian battery metals projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NOVONIX Limited (NVX) ORDINARY FULLY PAID |
Information Technology |
$215 |
NOVONIX Finalises PSA for Enterprise South Land
|
30 Apr 2025 8:30AM |
$0.450 |
$0.250 |
fallen by
44.44%
|
|
NVX - Price-sensitive ASX Announcement
Full Release
Key Points
- NOVONIX Limited has finalised a Project Site Agreement (PSA) for the Enterprise South Industrial Park in Chattanooga, Tennessee.
- The PSA secures the location for a planned 30,000 tpa synthetic graphite anode material facility.
- This facility is integral to NOVONIX’s strategy for domestic battery material supply in North America.
- The agreement involves steps for site acquisition, development milestones, and coordination with local and state agencies.
- NOVONIX is advancing funding initiatives and regulatory processes to support project execution.
- The company is focused on serving the electric vehicle and energy storage sectors with US-made materials.
- The announcement highlights NOVONIX's commitment to sustainability and enhancing North American supply chain resilience.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Computershare Limited (CPU) ORDINARY FULLY PAID |
Industrials |
$17,456 |
Update - Notification of buy-back - CPU
|
30 Apr 2025 8:29AM |
$40.250 |
$30.180 |
fallen by
25.02%
|
|
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$30 |
Quarterly Activity Report - Q3 FY25
|
30 Apr 2025 8:29AM |
$0.095 |
$0.062 |
fallen by
34.74%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- Provided update on progress of clinical trials and regulatory milestones.
- Highlighted key commercial activities and expansion into new markets.
- Reported sales growth and interest in musculoskeletal CT imaging solutions.
- Outlined financial position including cash reserves and quarterly expenditures.
- Discussed ongoing product development and enhancement efforts.
- Described partnerships and collaborations to support growth.
- Mentioned regulatory submissions and approvals received in the quarter.
- Detailed upcoming business development and market expansion initiatives.
- Emphasized strengthening of product portfolio and market presence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$30 |
Quarterly Appendix 4C Cash Flow Report
|
30 Apr 2025 8:29AM |
$0.095 |
$0.062 |
fallen by
34.74%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Appendix 4C Cash Flow Report released for the quarter ended 31 March 2024.
- Net cash outflows from operating activities due to research and development, staff costs, and administration expenses.
- Receipts from customers were recorded, but operating cash outflows led to negative net operational cash flow.
- Details of cash balances at the end of the quarter provided.
- Payments to related parties and associates disclosed.
- Report includes a compliance statement with ASX Listing Rules.
- Commentary on ongoing business activities, including research and commercialization of medical imaging products.
- Company outlines funding position and anticipated need for further funding for continued growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tryptamine Therapeutics Limited (TYP) ORDINARY FULLY PAID |
Health Care |
- |
Quarterly Activities Report and Appendix 4C
|
30 Apr 2025 8:29AM |
$0.032 |
$0.034 |
risen by
6.25%
|
|
TYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of the first phase of Phase 2a clinical trial for treatment-resistant depression.
- Presentation of positive initial results from clinical trials.
- Ongoing engagement with regulatory agencies to support clinical programs.
- Development and expansion of intellectual property portfolio.
- Appendix 4C shows strong financial management and a solid cash position.
- Focus on clinical development, regulatory strategy, and operational execution.
- Commitment to delivering innovative psychedelic-assisted therapies.
- Proactive communication with stakeholders and market.
- No significant negative events or setbacks reported during the quarter.
- Company is well-positioned to achieve its near-term and long-term objectives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Southern Palladium Limited (SPD) ORDINARY FULLY PAID |
Materials |
$188 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:29AM |
$0.225 |
$1.495 |
risen by
564.44%
|
|
SPD - Price-sensitive ASX Announcement
Full Release
Key Points
- Scoping Study for Bengwenyama PGM project completed, confirming robust project economics.
- Key drilling results received, supporting Mineral Resource estimates and potential project expansion.
- Community and environmental engagement activities continued, reinforcing SPD’s commitment to ESG principles.
- Preparations underway for a Pre-Feasibility Study scheduled for the coming quarters.
- Ongoing drilling programs focused on resource definition and exploration.
- Quarterly cash outflows were in line with expectations, and the company maintained a strong cash position.
- No significant production or revenue was reported, as the company remains in the exploration and development stage.
- No material changes in tenements or issued capital during the quarter.
- SPD continues to monitor and manage geopolitical and operational risks associated with South African projects.
- Financial and operational activities were detailed in the Appendix 5B Cash Flow Report, highlighting major expenditure categories.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$77 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2025 8:28AM |
$0.053 |
$0.150 |
risen by
183.02%
|
|
ATX - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities and Appendix 4C Cash Flow Report released for period ending 31 March 2024.
- Lead drug AMP945 in active Phase 2 clinical trial (ACCENT) for pancreatic cancer, with positive recruitment progress.
- Preparations ongoing for INSPIRE Phase 2 trial in idiopathic pulmonary fibrosis (IPF), with regulatory and site activation steps underway.
- Financially, Amplia completed a $6.8 million capital raise and ended the quarter with $10.1 million in cash.
- Expenditure focused on clinical trial activities, research, and operational support.
- No payments were made to related parties or their associates during the quarter.
- Strong engagement maintained with clinical partners, investigators, and global regulatory agencies.
- Company remains on track to meet clinical milestones and further development objectives in 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ecofibre Limited (EOF) ORDINARY FULLY PAID |
Health Care |
- |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2025 8:28AM |
$0.022 |
$0.020 |
fallen by
9.09%
|
|
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$1,916 |
Ceasing to be a substantial holder
|
30 Apr 2025 8:28AM |
$16.310 |
$16.570 |
risen by
1.59%
|
|
| Sierra Nevada Gold Inc. (SNX) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$27 |
Annual Report to Securityholders
|
30 Apr 2025 8:28AM |
$0.018 |
$0.055 |
risen by
205.56%
|
|
| Sierra Nevada Gold Inc. (SNX) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$27 |
Notice of Annual General Meeting/Proxy Form
|
30 Apr 2025 8:28AM |
$0.018 |
$0.055 |
risen by
205.56%
|
|
| Matsa Resources Limited (MAT) ORDINARY FULLY PAID |
Materials |
$65 |
Secondary Trading Notice
|
30 Apr 2025 8:27AM |
$0.065 |
$0.067 |
risen by
3.08%
|
|
Call 1300 880 160
Start a chat
Schedule a call
